NASDAQ$VTYX
Ventyx Biosciences Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2023.
Ventyx Biosciences reported a net loss of $38.9 million for the first quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $376.9 million as of March 31, 2023, which is expected to fund operations into 2025. Five Phase 2 clinical trials are ongoing.
- Phase 2 trials of VTX958 are ongoing in plaque psoriasis, Crohn’s disease and psoriatic arthritis, with topline data in plaque psoriasis expected in Q4 2023.
- The Phase 2 trial of VTX002 in ulcerative colitis is progressing, with topline data expected in H2 2023.
- Cash, cash equivalents and marketable securities were $376.9 million as of March 31, 2023, expected to fund planned operations into 2025.
- A Phase 1 trial of CNS-penetrant NRLP3 inhibitor VTX3232 is expected to be initiated this quarter.
Headline financials
Revenue & EPS history
Ventyx Biosciences · Revenue · Quarterly
$150M
Forward guidance
Ventyx anticipates key milestones in its clinical programs and expects current resources to fund operations into 2025.
Tailwinds
- Anticipated timing of commencement, enrollment and completion of clinical trials for Ventyx’s product candidates
- Anticipated timing for releasing topline data for clinical trials of Ventyx’s product candidates
- Anticipated timing for providing an update on VTX958 extended release tablet development
- Anticipated timing for nominating a lead candidate for the IL-4Rα discovery program
- Expected timeframe for funding Ventyx’s operating plan with current cash, cash equivalents and marketable securities
Headwinds
- Potential delays in the commencement, enrollment and completion of clinical trials
- Dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing
- Disruptions in the supply chain, including raw materials needed for manufacturing and animals used in research, delays in site activations and enrollment of clinical trials
- Unexpected adverse side effects or inadequate efficacy of Ventyx’s product candidates that may limit their development, regulatory approval and/or commercialization, or may result in recalls or product liability claims
- Disruption to Ventyx’s operations from the ongoing global outbreak of the COVID-19 pandemic, or from the ongoing military conflict in Ukraine, including clinical trial delays
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports
+4.2%
Avg return
Earnings day
+7.1%
Avg return
5 days after
+13.8%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+34.4%
Q2 2022
Best reaction
-11.9%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -5.7% | +2.5% | -6.0% | |
| Q2 2025 | +18.4% | +20.5% | +6.8% | |
| Q1 2025 | +7.0% | +1.8% | +113.2% | |
| Q4 2024 | +9.0% | +4.2% | -16.1% | |
| Q3 2024 | -5.6% | -10.0% | +34.2% | |
| Q2 2024 | +5.6% | -0.5% | +10.9% | |
| Q1 2024 | -7.9% | -6.3% | -26.4% | |
| Q4 2023 | +32.6% | +45.0% | -6.5% | |
| Q3 2023 | -11.9% | — | — | |
| Q2 2023 | +1.9% | — | — | |
| Q1 2023 | -11.6% | — | — | |
| Q4 2022 | -8.3% | — | — | |
| Q3 2022 | -9.1% | — | — | |
| Q2 2022 | +34.4% | — | — | |
| Q1 2022 | +10.6% | — | — | |
| Q2 2021 | +9.3% | — | — | |
| Q4 2021 | +9.3% | — | — | |
| Q3 2021 | -1.7% | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro